Abstract
The novel RGDF mimetics 9a and 9b were synthesized with the use of 4-(isoindoline-5-yl)amino-4-oxobutyric acid as a surrogate of Arg-Gly motif. The synthesized compounds have demonstrated a high potency to inhibit platelet aggregation in vitro and to block FITC-Fg binding to alpha(IIb)beta(3) on washed human platelets.
MeSH terms
-
Butyrates / chemical synthesis*
-
Butyrates / chemistry
-
Butyrates / pharmacology*
-
Drug Evaluation, Preclinical
-
Humans
-
Indoles / chemical synthesis*
-
Indoles / chemistry
-
Indoles / pharmacology*
-
Isoindoles
-
Molecular Mimicry
-
Molecular Structure
-
Oligopeptides / chemical synthesis*
-
Oligopeptides / chemistry
-
Oligopeptides / pharmacology*
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / chemical synthesis*
-
Platelet Aggregation Inhibitors / chemistry
-
Platelet Aggregation Inhibitors / pharmacology*
-
Platelet Membrane Glycoproteins / antagonists & inhibitors
-
Receptors, Fibrinogen / antagonists & inhibitors*
-
Structure-Activity Relationship
Substances
-
4-(isoindoline-5-yl)amino-4-oxobutyric acid
-
Butyrates
-
Indoles
-
Isoindoles
-
Oligopeptides
-
Platelet Aggregation Inhibitors
-
Platelet Membrane Glycoproteins
-
Receptors, Fibrinogen
-
arginyl-glycyl-aspartyl-phenylalanine